Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Device Industry Amps Up Efforts To Repeal Device Tax In Lame Duck Session

This article was originally published in The Gray Sheet

Executive Summary

Industry groups flew in more than 50 CEOs to visit Capitol Hill, launched an ad campaign and released an impact report last week as part of a stepped-up effort to get Congress to repeal the impending medical device tax before it goes into effect Jan. 1.


Related Content

Industry Efforts Against Device Tax Haven't Slowed Down, Despite Suspension
PhRMA CEO: Ubl Pick Brings User Fee, Reimbursement Expertise
PhRMA CEO: Ubl Pick Would Bring User Fee, Reimbursement Expertise
AdvaMed Launches National Search For New CEO As Ubl Plans Departure
Ultimate Burden Of Device Tax – After Deductions – Debated At Senate Hearing
Post-Election Picture: Near-Term Next Steps To Come
Device Tax Repeal Tops AdvaMed Priority List For Fiscal-Cliff Bill
House Adds Momentum, But Big Barriers To Device Tax Repeal Remain
Device Tax Repeal As Tax Reform: AdvaMed Makes The Case
AdvaMed Steps Up Effort To Link Device Tax Repeal To Job Growth





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts